Natixis Bleichroeder Starts Quest Diagnostics (DGX) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- S&P 500 ends higher as traders shift from AI to healthcare
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
Tweet
Share
E-mailGet Alerts DGX Hot Sheet
Price: $239.15 +2.45%
Rating Summary:
15 Buy, 17 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 13 | New: 42
Rating Summary:
15 Buy, 17 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 13 | New: 42
Join SI Premium – FREE
Natixis Bleichroeder initiates coverage on Quest Diagnostics (NYSE: DGX) with a Buy. PT $59.00.
For more ratings news on Quest Diagnostics click here and for the rating history of Quest Diagnostics click here.
Shares of Quest Diagnostics closed at $50.36 yesterday.
For more ratings news on Quest Diagnostics click here and for the rating history of Quest Diagnostics click here.
Shares of Quest Diagnostics closed at $50.36 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Starts Figure Technology (FIGR) at Buy
- JPMorgan Starts Glencore Plc (GLC:AU) (GLCNF) at Overweight
- Stephens Assumes nCino Inc. (NCNO) at Overweight
Create E-mail Alert Related Categories
New CoverageRelated Entities
Natixis BleichroederSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
